Welcome to our dedicated page for Biomx news (Ticker: PHGE), a resource for investors and traders seeking the latest updates and insights on Biomx stock.
BiomX Inc. (PHGE) news is centered on the company’s transition from a legacy phage therapy profile toward defense, security, critical infrastructure, and first-response technologies. Recent company announcements focus heavily on Zorronet, an AI defense technology subsidiary that develops command-and-control, computer vision, and autonomous surveillance systems.
PHGE news can include acquisition updates, material agreements, customer deployments, and operating details tied to Zorronet and DFSL. Zorronet-related coverage has included AI command-and-control software, secure on-premise and hybrid C5ISR deployments, mobile field-operator tools, and the use of cameras, sensors, drones, and IoT devices in integrated security environments.
Infrastructure and government-related items are also important for BiomX coverage. Company disclosures have discussed Zorronet’s work with Israel Railways, contracts with the Israel Defense Forces, and engagements involving government customers, Tier-1 OEMs such as Elbit Systems, and international clients. DFSL adds another news angle through LADAR-based detection systems for perimeter security, critical infrastructure, and counter-UAS markets.
BiomX news may also include SEC filing events, shareholder votes, governance changes, capital-structure disclosures, and operating results. Because the company has disclosed substantial doubt about its ability to continue as a going concern, financing and liquidity-related disclosures are also material to PHGE coverage. For investors tracking PHGE, the main news themes are defense technology acquisitions, operational deployments, critical infrastructure agreements, and the company’s remaining phage therapy background.
BiomX Inc. (NYSE American: PHGE) will present updated data from its Phase 1b/2a study of BX004 for treating cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections at the North American Cystic Fibrosis Conference in Boston. The findings will be showcased in a poster session on September 27, 2024, and discussed in a workshop on September 28, 2024.
Key results include:
- Greater reduction in P. aeruginosa colony-forming units in subjects receiving BX004-A compared to placebo
- 14% of BX004-A recipients had negative P. aeruginosa sputum culture at treatment end, versus 0% for placebo
- Improved lung function (FEV1) in a subgroup of BX004-A recipients (+5.66%) compared to placebo (-3.23%)
The study's six-month follow-up has been completed for all subjects.
BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing novel phage therapies targeting specific pathogenic bacteria, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel.
Key details include:
- CEO Jonathan Solomon will present a corporate overview
- Presentation Date: September 9, 2024
- Time: Available on-demand from 7:00 AM ET
- Webcast link provided for virtual attendance
- Replay available on BiomX's website for 90 days
Mr. Solomon will also be available for one-on-one meetings during the conference. Interested parties can register and request meetings through the provided link.
BiomX Inc. (NYSE American: PHGE) will present positive Phase 1b/2a clinical trial data for BX004, a novel phage therapy targeting Pseudomonas aeruginosa in cystic fibrosis patients, at the European Respiratory Society Congress 2024. The study demonstrated favorable safety and notable microbiologic and clinical efficacy, even in patients on standard care treatment. Key findings include:
1. Greater reduction in P. aeruginosa colony-forming units in treated subjects vs. placebo
2. 14% of treated subjects had negative P. aeruginosa sputum culture at treatment end
3. Improved lung function in a subgroup of treated patients
4. No treatment-related phage resistance or serious adverse events
BiomX CEO Jonathan Solomon expressed encouragement about the results, highlighting the potential of their novel approach in treating cystic fibrosis.
BiomX Inc. (NYSE American: PHGE) has announced a 1-for-10 reverse stock split of its common stock, effective August 26, 2024. The stock will continue trading under the symbol 'PHGE' with a new CUSIP number. This decision follows stockholder approval on July 9, 2024, and final ratio determination by the Board on August 8, 2024. The split will reduce outstanding shares from approximately 178,958,447 to 17,895,845.
Key points:
- Proportional adjustments will be made to equity awards, warrants, convertible preferred stock, and stock incentive plans
- Outstanding units will also undergo a 1-for-10 reverse split, trading under 'PHGE U'
- No fractional shares will be issued; stockholders entitled to fractional shares will receive an additional fraction to round up
- The split won't alter stockholders' percentage ownership, except for minor fractional share adjustments
BiomX Inc. (NYSE American: PHGE) has announced a 1-for-10 reverse stock split of its common stock, effective August 26, 2024. The stock will continue trading under the symbol 'PHGE' with a new CUSIP number. This decision, approved by stockholders on July 9, 2024, will reduce outstanding shares from approximately 178,958,447 to 17,895,845. The reverse split will not alter stockholders' ownership percentages, and fractional shares will be rounded up. No action is required for holders of book-entry or brokerage account shares. The company's units will be proportionally adjusted, maintaining one share and one warrant exercisable for half a share per unit.
BiomX Inc. (NYSE American: PHGE) reported Q2 2024 financial results and provided business updates. Key highlights include:
1. Anticipated readout of topline results for BX211 in Q1 2025 for diabetic foot osteomyelitis treatment.
2. Planned initiation of BX004 Phase 2b trial for cystic fibrosis, with results expected in Q3 2025.
3. Stockholder approval for conversion of Series X Preferred Stock to common stock.
4. Cash balance of $32.7 million as of June 30, 2024, sufficient to fund operations through Q4 2025.
5. Net income of $4.5 million for Q2 2024, compared to a net loss of $6.4 million in Q2 2023.
6. R&D expenses increased to $6.9 million in Q2 2024 from $3.8 million in Q2 2023.
BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing novel natural and engineered phage therapies targeting specific pathogenic bacteria, has announced a conference call and live audio webcast scheduled for August 15, 2024, at 8:00 a.m. ET. The purpose of this event is to report the company's second quarter 2024 financial results and provide updates on its business and programs.
Interested parties can participate in the conference call by dialing 1-877-407-0724 (U.S.) or 1-201-389-0898 (International). Additionally, a live and archived webcast will be available in the Investors section of the BiomX website at www.biomx.com.
BiomX Inc. (NYSE American: PHGE) has received acceptance from the NYSE American for its plan to regain listing compliance. The company, which develops phage therapies targeting specific pathogenic bacteria, was granted until November 23, 2025 to meet the continued listing standards. This follows a deficiency letter received on May 23, 2024, indicating non-compliance with Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide.
CEO Jonathan Solomon expressed satisfaction with the acceptance and stated that BiomX has already begun implementing its plan, including obtaining stockholder approval for converting outstanding Series X Convertible Preferred Stock to Common Stock. During the compliance period, BiomX will undergo periodic reviews by the NYSE American. Failure to regain compliance or make sufficient progress may result in delisting proceedings.
BiomX announced stockholder approval to convert its Series X Non-Voting Convertible Preferred Stock into common stock. The Series X Preferred Stock was issued during BiomX's acquisition of Adaptive Phage Therapeutics in March 2024 and a $50 million financing. The conversion will see up to 256,887,000 shares of common stock added to the outstanding share count. This move aims to help BiomX comply with NYSE American's listing requirement for $2 million in stockholders' equity, a condition they had previously failed to meet. The reclassification of proceeds from the Financing as stockholders' equity could help achieve compliance. BiomX's CEO highlighted the acquisition and financing milestones as important for BiomX's future growth, particularly with two Phase 2 clinical candidates expected to report significant results next year.
BiomX received a notice of non-compliance from NYSE American on May 23, 2024, due to failing to meet stockholders' equity requirements. The company has a capital deficiency of $9.54 million and reported losses for the past five fiscal years. The notice does not immediately affect the trading of BiomX shares, which will continue under the symbol 'PHGE' with a '.BC' designation for below compliance. BiomX must submit a compliance plan by June 22, 2024, and gain compliance by November 23, 2025, to avoid delisting. The company expects to resolve the equity issue by converting preferred stock to common stock, pending shareholder approval in July 2024.